Back to News
Market Impact: 0.3
Agenus' Q3 Earnings Match Estimates, Revenues Miss Mark, Stock Down
Source: zacks.com
Healthcare & BiotechCorporate EarningsAnalyst EstimatesCompany Fundamentals
AGEN’s Q3 earnings met estimates, but a revenue miss weighed on shares. Pipeline progress, drug approvals in Armenia, and new funding were also cited as key developments; the article provides no figures for these items.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly negative
Sentiment Score
-0.20
Ticker Sentiment
AGEN-0.20
More News
- Further turmoil could be in store for tech stocks. What to watch in the week ahead
- Elon Musk once said the Cybertruck would be Tesla’s ‘best product ever.’ Now he’s winding down production
- AI stocks hammered by midterm shock as data center buildout becomes a 'war of attrition'
- Fox completes its $22B acquisition of Roku
- Elanco Shares Jump After Q3 Beat and Outlook Raise
- FTSE 100 today: Stocks slump as global tech rout deepens